Clinician’s Brief spotlights regenerative therapies in general practice: full analysis

Clinician’s Brief is putting regenerative medicine back in front of practicing veterinarians, this time through a sponsored podcast aimed squarely at general practice. In “Incorporating Regenerative Therapies Into Practice With Dr. Malhotra,” published in May 2026, Rohit Malhotra, DVM, MBA, joins host Beth Molleson, DVM, to discuss what regenerative medicine includes, which patients may benefit, and how clinics can realistically add these therapies to practice workflows. The episode is sponsored by Hilltop Bio. (cliniciansbrief.com)

That framing matters because regenerative medicine has spent years in veterinary care as a mix of promise, uneven adoption, and regulatory ambiguity. FDA’s Center for Veterinary Medicine says animal cells, tissues, and cell- and tissue-based products, or ACTPs, are under active oversight, and its guidance makes clear that many cell-based products intended to treat disease or affect structure or function meet the definition of a new animal drug. Separately, the Merck Veterinary Manual says no cell-based regenerative treatment is currently FDA-approved for veterinary use in the U.S., and it highlights the field’s lack of consensus on sourcing, dosing, timing, and adjunct protocols. (fda.gov)

Against that backdrop, the Clinician’s Brief episode appears less like a simple educational podcast and more like a marker of where the market is heading: from specialist-led use toward broader primary care adoption. The episode description explicitly says regenerative medicine is “no longer just for specialty centers,” and positions the real challenge as implementation in general practice. That includes deciding what regenerative medicine actually means in a clinic setting, identifying appropriate patients, and understanding the operational lift needed for successful rollout. (cliniciansbrief.com)

The sponsor context is also relevant. Hilltop Bio describes itself as a regenerative biologics company serving canine and equine practice, says its products are used in more than 1,000 clinics, and says it is conducting four targeted studies intended to generate data relevant to FDA regulatory standards. The company’s public-facing materials emphasize biologically derived formulations and contrast them with symptom-focused treatments such as steroids and NSAIDs. That doesn’t validate any individual product claim on its own, but it does show how companies in this segment are trying to position regenerative therapies: not as fringe add-ons, but as a more mainstream part of recovery and orthopedic care. (hilltopbio.com)

Broader veterinary conversation supports that shift, but with caveats. Clinician’s Brief recently ran another podcast on canine therapeutic joint injections that discussed commonly used intra-articular options including triamcinolone, hyaluronic acid, and platelet-rich plasma, suggesting orthobiologics are already part of the clinical discussion around multimodal joint care. Meanwhile, AVMA coverage and journal-related reporting show regenerative medicine remains an active research area, including systematic review work on stem cells and platelet-rich plasma in equine tendon and ligament injuries. (cliniciansbrief.com)

Why it matters: For veterinary professionals, the practical question is no longer whether pet parents will ask about regenerative options. Many already are, especially in osteoarthritis, sports medicine, rehabilitation, and post-procedural recovery. The harder question is how to separate credible, workflow-ready offerings from marketing that outruns the evidence. Clinics considering adoption will need to weigh patient selection, sedation and sterility requirements for injection-based therapies, staff training, informed consent, pricing, and follow-up expectations, while also checking whether a given product is a device, a biologic, or a product that may fall under FDA drug oversight. (cliniciansbrief.com)

There’s also a business dimension. Malhotra’s background appears to span both veterinary and practice leadership, and the episode’s emphasis on bringing regenerative medicine into general practice suggests this is as much about service-line strategy as it is about clinical science. That may resonate with practices looking for differentiated musculoskeletal and recovery offerings, but it also raises the bar for due diligence. Inference: educational content tied to a sponsor in a fast-moving therapeutic category is likely to be most useful when paired with independent review of regulatory status, published evidence, and case selection protocols. (cliniciansbrief.com)

What to watch: Watch for more vendor-backed education, more clinic-level adoption of PRP and related orthobiologics, and more scrutiny of product classification and evidence as FDA guidance on animal cell- and tissue-based products continues to shape the category. (fda.gov)